Moleculin Biotech Inc (MBRX) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access MBRX Annual Balance Sheets →
Balance sheet performance over multiple periods helps investors evaluate the financial resilience of Moleculin Biotech Inc.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent7.26
Cash & Short-term Investments7.00
Notes, Loans and Financing Receivable, Net, Current AC0.00
Prepaid Expense And Other Assets Current2.50
Total Current Assets8.72
Equipment/Property/Plant Net0.06
Intangible Assets11.15
Other Assets, Noncurrent0.12
Operating Lease Right Of Use Asset0.28
Total Assets21.09
Liabilities
Accounts Payable, Current AC4.34
Accrued Liabilities, Current AC4.98
Total Current Liabilities9.31
Total Long-term Debt0.00
Derivative Liability, Noncurrent DE0.04
Other liabilities, Noncurrent0.15
Operating Lease Liability Noncurrent0.19
Total Liabilities9.50
Stockholders' Equity
Aoci Before Tax Attributable To Parent-
Common Stock Value0.01
Additional Paid In Capital Common Stock238.13
Retained Earnings / Accumulated Deficit-226.48
Accumulated Other Comprehensive Income-0.06
Other Equity-0.06
Common Stockholder's Equity11.59
Total Stockholder's Equity11.59
Liabilities & Stockholder's Equity21.09
4 historic quarters locked

Sign in to unlock the full Moleculin Biotech Inc balance sheet history.

About Moleculin Biotech Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001437749-26-027688

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.